Studies
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Request Access
Overview
Selected Publications (6)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan, Martin C. Whittle, K. Nakamura, et al.. (2012). Cell. Cited 718 times.
https://doi.org/10.1016/j.cell.2012.02.053
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
J. Zawistowski, Samantha M. Bevill, D. Goulet, et al.. (2017). Cancer discovery. Cited 145 times.
https://doi.org/10.1158/2159-8290.CD-16-0653
Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
Gary L. Johnson, T. Stuhlmiller, Steven P. Angus, et al.. (2014). Clinical Cancer Research. Cited 119 times.
https://doi.org/10.1158/1078-0432.CCR-13-1081
Defining the expressed breast cancer kinome
Alicia A Midland, Martin C. Whittle, James S. Duncan, et al.. (2012). Cell Research. Cited 28 times.
https://doi.org/10.1038/cr.2012.25
Assessing adaptation of the cancer kinome in response to targeted therapies.
J. Zawistowski, L. Graves, G. Johnson. (2014). Biochemical Society transactions. Cited 8 times.
https://doi.org/10.1042/BST20130274
Landscaping a chromatin response to MEK inhibition
J. Zawistowski, D. Goulet, G. Johnson. (2017). Cell Cycle. Cited 1 times.
https://doi.org/10.1080/15384101.2017.1302232
